Inari VISION Registry
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ida Nelson
- Phone Number: 46 707 723010
- Email: ida.nelson@inarimedical.com
Study Locations
-
-
-
Ancona, Italy
- Recruiting
- Azienda Ospedaliero Universitaria delle Marche
-
Contact:
- Tommaso Piva, MD
-
-
-
-
-
Lisbon, Portugal
- Recruiting
- Santa Marta Hospital
-
Contact:
- Luís Almeida Morais, MD
-
-
-
-
-
Bristol, United Kingdom
- Recruiting
- Southmead Hospital Bristol
-
Contact:
- Peter Mezes, MD
-
Glasgow, United Kingdom
- Recruiting
- Queen Elizabeth University Hospital
-
Contact:
- Peter Douglas, MBChB
-
London, United Kingdom
- Recruiting
- Royal Free Hospital
-
Contact:
- Tushar Kotecha, PhD
-
London, United Kingdom
- Recruiting
- Northwick Park Hospital
-
Contact:
- Jaymin Shah, MD
-
London, United Kingdom
- Recruiting
- UCLH University College London Hospital
-
Contact:
- Conrad von Stempel, MBBS
-
London, United Kingdom
- Recruiting
- Royal London
-
Contact:
- Rashid Akhtar, MBBS
-
Newcastle, United Kingdom
- Recruiting
- Royal Victoria Infirmary
-
Contact:
- John Reicher, BM BCh
-
Swindon, United Kingdom
- Recruiting
- Great Western Hospital
-
Contact:
- Steve Ramcharitar, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Willing and able to provide informed consent per institution and geographical requirements
- Has received treatment with an eligible Inari Medical device. NOTE: If patients are consented prior to their procedure and the procedure does not take place, the patient will be considered a screen failure.
- Currently within enrollment window relative to their procedure
- Age ≥ 18 years
Exclusion Criteria:
- Is or will be inaccessible for registry follow-up
- Meets exclusion criteria required by local requirements
- Current or planned participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this registry
- Is pregnant or breastfeeding at the time of enrollment
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of device-related, procedure-related, or fatal Adverse Events
Time Frame: Up to 180 days
|
Up to 180 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 24-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.